PASADENA

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

Topic / Pathology

  • Parkinson's Disease

Objectives

To have more informations, click on the link below: 

https://clinicaltrials.gov/ct2/show/NCT03100149?term=pasadena&cond=Parkinson&rank=1

Sponsor

Hoffmann-La Roche

Scientific publication(s)

  • Jankovic J et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.

    https://pubmed.ncbi.nlm.nih.gov/29913017/

Status

Published results

Participating centers

Share

Updated on 17 February 2023